Our Next Show: New Myeloma Solutions for Relapsed/Refractory Patients with Dr. Ravi Vij, Washington University School of Medicine
Listen Live via Computer What are the best approaches for later stage, aggressive myeloma? Dr. Ravi Vij shares newer solutions now in early clinical trials for relapsed/refractory patients. Dr. Ravi Vij, MD, is Associate Professor of Medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia at the Washington University School of Medicine in St. Louis. Dr. Vij is a member of several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, the St. Louis Society of Clinical Oncology, and the American Association for the Advancement of Science. He also serves on numerous national committees, including the Myeloma, Transplant, Leukemia Committees of the Alliance for Clinical Trials in Oncology (CALGB) and the Steering Committee of the Multiple Myeloma Research Consortium. His honors include the Multiple Myeloma Research Foundation Innovator Award (2013) and the Multiple Myeloma Research Consortium Center of Excellence Award (2011). The author of over 100 peer-reviewed publications, as well as a book (Contemporary Management of Multiple Myeloma, 2012, JP Medical Publishers), and several book chapters, Dr. Vij has also served as a reviewer for several journals, including Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Experimental Hematology, and Haematologica. His primary academic interests include the treatment of multiple myeloma and hematopoietic stem cell transplantation for hematologic malignancies. He leads numerous clinical trials and has established a large myeloma tissue repository at Washington University and has extensive active collaborations to study the biology of the disease with a strong institutional focus on genomics of the disease. Dr. Vij lectures extensively on the topic of multiple myeloma and plasma cell dyscrasias.